Royalty Pharma (RPRX) Revenue (2019 - 2026)

Royalty Pharma has reported Revenue for 8 years, with the latest figure at $630.6 million in Q1 2026.

• Quarterly Revenue rose 10.97% year-over-year to $630.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 7.8% YoY) and the FY2025 annual result came in at $2.4 billion, up 5.06% from the prior year.
• Revenue rose to $630.6 million in Q1 2026 per RPRX's latest filing, from $622.0 million in the prior quarter.
• Over five years, Revenue peaked at $684.0 million in Q1 2023 and troughed at $536.0 million in Q2 2022.
• A 5-year average of $580.2 million and a median of $568.2 million in 2025 frame the typical range for Revenue.
• The sharpest annual moves came in 2023 and 2024: Revenue rose 21.69% in 2023, then fell 16.96% in 2024.
• Over 5 years, Revenue stood at $565.7 million in 2022, then gained by 5.36% to $596.1 million in 2023, then retreated by 0.41% to $593.6 million in 2024, then increased by 4.78% to $622.0 million in 2025, then rose by 1.38% to $630.6 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $630.6 million, $622.0 million, and $609.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.